title: Reducing angiographic cystoid macular edema and blood-aqueous barrier disruption after small-incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0.1% and betamethasone 0.1%.
abstract: OBJECTIVE
  To compare the effectiveness of a topical nonsteroidal drug (diclofenac 0.1%) and a topical steroidal drug (betamethasone 0.1%) in preventing cystoid macular edema (CME) and blood-aqueous barrier (BAB) disruption after small-incision cataract surgery and foldable intraocular lens (IOL) implantation.
  
  
  METHODS
  Shohzankai Medical Foundation Miyake Eye Hospital, Tokyo, Japan.
  
  
  METHODS
  This multicenter interventional double-masked randomized study comprised 142 patients having phacoemulsification and foldable IOL implantation. Seventy-one patients were randomized to receive diclofenac eyedrops and 71, betamethasone eyedrops for 8 weeks postoperatively. The incidence and severity of CME were evaluated by fluorescein angiography. Blood-aqueous barrier disruption was determined by laser flare-cell photometry.
  
  
  RESULTS
  Of the patients, 63 were men and 79 were women. Five weeks after surgery, the incidence of fluorescein angiographic CME was lower in the diclofenac group (18.8%) than in the betamethasone group (58.0%) (P<.001). At 1 and 2 weeks, the amount of anterior chamber flare was statistically significantly less in the diclofenac group than in the betamethasone group (P<.05). At 8 weeks, intraocular pressure was statistically significantly higher in the betamethasone group (P = .0003).
  
  
  CONCLUSIONS
  Diclofenac was more effective than betamethasone in preventing angiographic CME and BAB disruption after small-incision cataract surgery. Thus, nonsteroidal antiinflammatory agents should be considered for routine treatment of eyes having cataract surgery.
authors.affiliation: Shohzankai Medical Foundation, Miyake Eye Hospital, Kita-ku, Nagoya, Japan.
authors.forename: Sayaka
authors.initials: S
authors.lastname: Asano
authors.forename: Kensaku
authors.initials: K
authors.lastname: Miyake
authors.forename: Ichiro
authors.initials: I
authors.lastname: Ota
authors.forename: Gentaro
authors.initials: G
authors.lastname: Sugita
authors.forename: Wataru
authors.initials: W
authors.lastname: Kimura
authors.forename: Yuji
authors.initials: Y
authors.lastname: Sakka
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Yabe
mesh_terms: D000287:Administration, Topical; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D001623:Betamethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D018916:Blood-Aqueous Barrier / Q000187:drug effects*; D002199:Capillary Permeability / Q000187:drug effects; D004008:Diclofenac / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005451:Fluorescein Angiography; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D007429:Intraocular Pressure / Q000187:drug effects; D019654:Lens Implantation, Intraocular / Q000009:adverse effects*; D008269:Macular Edema / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D018918:Phacoemulsification / Q000009:adverse effects*; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D005938:Glucocorticoids; D004008:Diclofenac; D001623:Betamethasone